This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Randomized Contralateral Clinical Trial With Single-piece (SN60WF) vs. Three Piece (MA60AC) AcrySof Intraocular Lenses (IOLs) on Development of Posterior Chamber Opacification (PCO).

This study has been completed.
Information provided by (Responsible Party):
Alcon Research Identifier:
First received: September 23, 2008
Last updated: August 15, 2014
Last verified: August 2011
Randomized contralateral clinical trial with single piece (Model SN60WF) vs. three piece (Model MA60AC) AcrySof Intraocular Lenses (IOLs) on development of Posterior Chamber Opacifiation (PCO).

Condition Intervention
Cataract Device: Model SN60WF Device: Model MA60AC

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Posterior Capsule Opacification (PCO) [ Time Frame: Up to 3 years ]
    Development of PCO using the EPCO Score. The EPCO score incorporates planimetric & grading assessments. The density of the opacification behind the Intraocular Lens (IOL) is graded clinically as follows: 0=No detectable opacification; 1=Minimal detectable opacification; 2=mild detectable opacification; 3=moderate detectable opacification; 4=severe detectable opacification. The individual PCO score is calculated by multiplying the opacification grade by the fraction of capsule area involved behind the IOL optic. The selection process and grading of areas are subjective.

Enrollment: 81
Study Start Date: January 2006
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Model SN60WF
Implantation with the AcrySof Model SN60WF Intraocular Lens (IOL)
Device: Model SN60WF
Implantation with the AcrySof Model SN60WF Single-piece intraocular lens (IOL) following cataract removal.
Active Comparator: Model MA60AC
Implantation with the AcrySof Model MA60AC Intraocular Lens (IOL)
Device: Model MA60AC
Implantation with the AcrySof Model MA60AC multi-piece intraocular lens (IOL) following cataract surgery.


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age > 50 years
  • Clear cornea
  • Pupil mydriasis ≥ 7mm
  • In the bag Intraocular Lens (IOL)

Exclusion Criteria:

  • Ocular pathology - uveitis, glaucoma, pseudoexfoliation syndrome (PEX), high myopia
  • Previously operated eye
  • Proliferative diabetic retinopathy
  • Surgical complications - incomplete rhexis, post capsular rupture (PCR), zonular dialysis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00758745

United States, Texas
Contact Alcon Call Center for Study Locations
Fort Worth, Texas, United States, 76134
Sponsors and Collaborators
Alcon Research
  More Information

Responsible Party: Alcon Research Identifier: NCT00758745     History of Changes
Other Study ID Numbers: P-06-03
Study First Received: September 23, 2008
Results First Received: July 1, 2011
Last Updated: August 15, 2014

Keywords provided by Alcon Research:
age related

Additional relevant MeSH terms:
Lens Diseases
Eye Diseases processed this record on September 19, 2017